Raymond James & Associates Sells 1,564 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Raymond James & Associates reduced its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 4.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,846 shares of the specialty pharmaceutical company’s stock after selling 1,564 shares during the quarter. Raymond James & Associates owned 0.05% of Jazz Pharmaceuticals worth $4,040,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JAZZ. Captrust Financial Advisors raised its position in shares of Jazz Pharmaceuticals by 2.4% in the first quarter. Captrust Financial Advisors now owns 3,707 shares of the specialty pharmaceutical company’s stock valued at $577,000 after purchasing an additional 86 shares during the period. First Republic Investment Management Inc. raised its position in shares of Jazz Pharmaceuticals by 0.7% in the fourth quarter. First Republic Investment Management Inc. now owns 12,062 shares of the specialty pharmaceutical company’s stock valued at $1,922,000 after purchasing an additional 88 shares during the period. Daiwa Securities Group Inc. raised its position in shares of Jazz Pharmaceuticals by 2.5% in the third quarter. Daiwa Securities Group Inc. now owns 4,076 shares of the specialty pharmaceutical company’s stock valued at $528,000 after purchasing an additional 100 shares during the period. Utah Retirement Systems raised its position in shares of Jazz Pharmaceuticals by 0.9% in the fourth quarter. Utah Retirement Systems now owns 10,836 shares of the specialty pharmaceutical company’s stock valued at $1,726,000 after purchasing an additional 100 shares during the period. Finally, Johnson Investment Counsel Inc. raised its position in shares of Jazz Pharmaceuticals by 0.8% in the third quarter. Johnson Investment Counsel Inc. now owns 13,096 shares of the specialty pharmaceutical company’s stock valued at $1,695,000 after purchasing an additional 110 shares during the period. 89.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

JAZZ has been the topic of several research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $180.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday. JPMorgan Chase & Co. upped their price target on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday, March 22nd. UBS Group decreased their price target on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a research note on Friday, March 1st. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 30th. Finally, Truist Financial restated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $195.08.

Insider Transactions at Jazz Pharmaceuticals

In related news, CFO Philip L. Johnson bought 12,000 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was purchased at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The purchase was disclosed in a document filed with the SEC, which is available through this link. In related news, CFO Philip L. Johnson bought 12,000 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was purchased at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, CAO Patricia Carr sold 1,936 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. Company insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Trading Down 2.6 %

Shares of Jazz Pharmaceuticals stock opened at $110.58 on Friday. The company has a market capitalization of $6.97 billion, a price-to-earnings ratio of 18.07, a PEG ratio of 1.58 and a beta of 0.59. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37. Jazz Pharmaceuticals plc has a 12-month low of $110.42 and a 12-month high of $147.14. The firm’s 50-day moving average price is $121.21 and its two-hundred day moving average price is $123.21.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. On average, analysts forecast that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.